帕博利珠单抗注射液致免疫性心肌炎合并重症肌无力1例分析

doi:10.19803/j.1672-8629.20240961

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (4): 464-466.
DOI: 10.19803/j.1672-8629.20240961

帕博利珠单抗注射液致免疫性心肌炎合并重症肌无力1例分析

陈亚丽¹, 郑小春^2,*

¹西宁市第一人民医院静配中心,青海西宁 810000;
²浙江省人民医院,杭州医学院附属人民医院药学部,浙江杭州 310014

收稿日期:2024-12-05 出版日期:2026-04-15 发布日期:2026-04-15
通讯作者: ^*郑小春,女,硕士,副主任药师,临床药学。E-mail: 13868109173@126.com
作者简介:陈亚丽,女,硕士,主管药师,临床药学。

One Case of Immune Myocarditis Complicated with Severe Myasthenia Gravis Caused by Pembrolizumab Injection

CHEN Yali¹, ZHENG Xiaochun^2,*

¹Department of Clinical Pharmacy, the First People’ s Hospital of Xining, Xining Qinghai 810000, China;
²Department of Pharmacy, Zhejiang Provincial People’ s Hospital, the People’ s Hospital of Hangzhou Medical College, Hangzhou Zhejiang 310014, China;

Received:2024-12-05 Online:2026-04-15 Published:2026-04-15

摘要/Abstract

摘要： 目的探讨帕博利珠单抗注射液（以下简称“帕博利珠单抗”）致免疫性心肌炎合并重症肌无力的病例,为临床使用帕博利珠单抗提供参考。方法分析1例患者因肺癌使用帕博利珠单抗出现免疫性心肌炎合并重症肌无力的诊疗过程。检索文献报道,讨论是否重启免疫检查点抑制剂治疗和临床应对策略。结果患者使用帕博利珠单抗6周后出现免疫性心肌炎合并重症肌无力,停用帕博利珠单抗并积极对症治疗后,心肌肌钙蛋白Ⅰ明显下降,眼部肌无力症状好转。结合相关文献分析,使用帕博利珠单抗后,可能出现免疫性心肌炎合并重症肌无力,需及时停药并尽快干预。结论帕博利珠单抗很可能导致患者出现免疫性心肌炎合并重症肌无力,临床治疗过程中应该予以重视。

关键词: 帕博利珠单抗, 免疫检查点抑制剂, 免疫性心肌炎, 重症肌无力, 药品不良反应, 肺癌

Abstract: Objective To explore one case of immune myocarditis complicated with myasthenia gravis caused by pabolizumab Injection so as to provide a reference for rational use of pabolizumab in clinic. Methods The diagnosis and treatment of one patient with autoimmune myocarditis complicated with myasthenia gravis due to lung adenocarcinoma and treated with pabolizumab were analyzed. Related literature was searched for to find out whether ICIs treatment could be restarted and what was the best coping strategy. Results The patient developed immune myocarditis complicated with myasthenia gravis about 6 weeks after pabolizumab was taken. After discontinuation of this drug and symptomatic treatment, cardiac troponin I decreased significantly and the symptoms of ocular myasthenia improved. It was found that immune myocarditis complicated with myasthenia gravis might occur following the use of pabolizumab, making it necessary to stop taking the drug and intervene as soon as possible. Conclusion Pabolizumab may lead to immune myocarditis complicated with myasthenia gravis, which deserves more attention.

Key words: Pembrolizumab Injection, Immune Checkpoint Inhibitors, Immune Myocarditis, Myasthenia Gravis, Adverse Drug Reaction, Lung Cancer

中图分类号:

陈亚丽, 郑小春. 帕博利珠单抗注射液致免疫性心肌炎合并重症肌无力1例分析[J]. 中国药物警戒, 2026, 23(4): 464-466.

CHEN Yali, ZHENG Xiaochun. One Case of Immune Myocarditis Complicated with Severe Myasthenia Gravis Caused by Pembrolizumab Injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(4): 464-466.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240961

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I4/464

参考文献

[1] The Chinese Society of Clinical Oncology Expert Committee on Cardio-Oncology. Chinese Expert Consensus on the Surveillance and Management of Immune Checkpoint Inhibitor-Related Myocarditis(2020)[J]. Chin J Clin Oncol(中国肿瘤临床), 2020, 47(20): 1027-1038.
[2] THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al.NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2[J]. J Natl Compr Canc Netw, 2024, 22(9): 582-592.
[3] TAJIRI K, IEDA M.Cardiac Complications in Immune Checkpoint Inhibition Therapy[J]. Frontiers in Cardiovascular Medicine, 2019, 6: 3.
[4] HU Y, LIU C, JIN S, et al.A Case of Subclinical Immune Checkpoint Inhibitor-Associated Myocarditis in Non-Small Cell Lung Cancer[J]. BMC Pulmonary Medicine, 2023, 23(1): 119.
[5] DONG H, QI Y, KONG X, et al.PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism[J]. Frontiers in Pharmacology, 2022, 13: 835510.
[6] WEI XB, YAN F.A Case Report of Myasthenia Gravis Combined with Immune-Associated Myocarditis after PD-1 Immunosuppressant Treatment[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2025, 45(11): 1321-1324.
[7] WU TX, ZHANG Y, SHI YF, et al.Immune Checkpoint Inhibitor-Associated Myositis, Myocarditis and Myasthenia Gravis Overlap Syndrome Based on the US FDA Adverse Event Reporting System[J].Central South Pharmacy(中南药学), 2023, 21(8): 2232-2237.
[8] LEI Y, ZHENG X, HUANG Q, et al.Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: a Retrospective Analysis of Real World Data[J]. Frontiers in pharmacology, 2022, 13: 914928.
[9] TANG X, LI Y, HUANG H, et al.Early Evaluation of Severe Immune Checkpoint Inhibitor-Associated Myocarditis: a Real-World Clinical Practice[J]. Journal of Cancer Research and Clinical Oncology, 2023, 149(11): 8345-8357.
[10] PUZANOV I, SUBRAMANIAN P, YATSYNOVICH YV, et al.Clinical Characteristics, Time Course, Treatment and Outcomes of Patients with Immune Checkpoint Inhibitor-Associated Myocarditis[J]. Journal for Immunotherapy of Cancer, 2021, 9(6): e002553.
[11] CHEN JJ, QIAN PP, CAO K.Comparison and Analysis of Causality Assessment Method in China and Naranjo’s Method in the Evaluation of Adverse Drug Reactions[J]. Chinese Pharmaceutical Affairs(中国药事), 2020, 34(8): 988-992.
[12] HUANG YT, CHEN YP, LIN WC, et al.Immune Checkpoint Inhibitor-Induced Myasthenia Gravis[J]. Frontiers in Neurology, 2020, 11: 634.
[13] WU NC, FENG YH, KUO YH, et al.Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities[J]. Acta Cardiologica Sinica, 2022, 38(1): 39-46.
[14] GAO JX, LIU XX, XIA H.Research Progress of Inhibitor Associated Myocarditisat Immune Checkpoint[J]. Chin J Diffic and ComplCas(疑难病杂志), 2022, 21(12): 1311-1319.
[15] LIU YL, HE ZY.Analysis of Pembrolizumab Associated Myasthenia Gravis Based on Literature Reviews[J]. Chinese Journal of Pharmacoe-pidemiology(药物流行病学杂志), 2022, 31(6): 421-426.
[16] ZUBAIR AS, ROY B, BAEHRING JM, et al.Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management[J]. Cureus, 2022, 14(10): e30638.
[17] JOHNSON DB, MENZIES AM.Combination Immunomodulation for Immune-Checkpoint-Inhibitor-Associated Myocarditis[J]. Nature Reviews Clinical Oncology, 2023, 20(7): 427-428.
[18] MARCO C, SIMÓ M, ALEMANY M, et al.Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: an Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series[J]. Journal of Clinical Medicine, 2022, 12(1):130.
[19] PALASKAS NL, SEGURA A, LELENWA L, et al.Immune Checkpoint Inhibitor Myocarditis: Elucidating the Spectrum of Disease through Endomyocardial Biopsy[J]. European Journal of Heart Failure, 2021, 23(10): 1725-1735.
[20] WANG X, CHEN WY.Pharmaceutical Monitoring of Immunohepatitis Caused by PD-L1 Inhibitor: a Case Study[J]. Chinese Journal of Pharma-covigilance(中国药物警戒), 2021, 18(7): 693-696.

帕博利珠单抗注射液致免疫性心肌炎合并重症肌无力1例分析

One Case of Immune Myocarditis Complicated with Severe Myasthenia Gravis Caused by Pembrolizumab Injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	许卓欣, 张冰, 张晓朦, 孟敏, 萨日娜. 基于风险管理闭环模型构建的医疗机构药物警戒实践策略思考[J]. 中国药物警戒, 2026, 23(4): 438-442.
[2]	朱会卷, 王芳, 王丹, 任经天. 二羟丙茶碱注射剂安全性风险分析[J]. 中国药物警戒, 2026, 23(4): 456-459.
[3]	方威, 王焕萍, 朱红霞. 唑来膦酸注射液致中性粒细胞缺乏症1例分析[J]. 中国药物警戒, 2026, 23(4): 467-469.
[4]	司刘哲, 邓瑞, 刘琪, 原明亮, 屈冰, 张爱玲, 韩雪, 柴玉娜. 苹果酸舒尼替尼胶囊致下消化道出血1例分析[J]. 中国药物警戒, 2026, 23(4): 473-475.
[5]	秦博, 李根, 杜宇, 高山, 兰姗, 彭丹, 江永贤. 某省未成年人群应用阿奇霉素安全性风险分析[J]. 中国药物警戒, 2026, 23(3): 302-306.
[6]	蒋艳林, 邓俊刚, 陈薇, 张晶晶, 方春霞, 覃忠于, 彭英知, 郭冰, 廖儒佳. 注射用卡瑞利珠单抗致严重不良反应及风险因素分析[J]. 中国药物警戒, 2026, 23(3): 307-311.
[7]	黄丽, 张了云, 付敏, 李根, 杜宇, 高山, 兰姗, 彭丹, 江永贤. 209例尖吻蝮蛇血凝酶不良反应报告分析[J]. 中国药物警戒, 2026, 23(3): 312-317.
[8]	王雨婷, 朱芳仪, 吕欣鸽, 潘晨, 武一, 崔向丽. 免疫检查点抑制剂致肠炎病例分析[J]. 中国药物警戒, 2026, 23(3): 318-322.
[9]	栗玉杰, 马健桐, 张文静, 郭浩. 注射用伏立康唑不良反应特征及危险因素分析[J]. 中国药物警戒, 2026, 23(3): 323-327.
[10]	吉柳, 郝敏, 武文慧. 注射用紫杉醇脂质体致乙二胺四乙酸依赖性假性血小板减少症1例分析[J]. 中国药物警戒, 2026, 23(3): 334-336.
[11]	王蕾, 张立超, 钱凤丹. 注射用头孢哌酮钠舒巴坦钠联用去乙酰毛花苷注射液致双硫仑样反应1例分析[J]. 中国药物警戒, 2026, 23(3): 337-339.
[12]	李佳希, 雷晓天, 赵科, 牛丽, 孙阳, 钟怀乐, 郭浩. 结核菌素纯蛋白衍生物致过敏性休克1例分析[J]. 中国药物警戒, 2026, 23(3): 340-342.
[13]	曹阳, 付晓秀, 马林. 盐酸替罗非班氯化钠注射液致血栓性血小板减少性紫癜1例分析[J]. 中国药物警戒, 2026, 23(3): 346-348.
[14]	龙欢, 王凯鑫, 杨悦琦, 安明惠, 梁雨薇, 刘红冉, 高旭, 张丽, 丁佳欣, 宫建. 辐射防治药物警戒研究[J]. 中国药物警戒, 2026, 23(3): 355-360.
[15]	邓青青, 姚青青, 胡涛, 杨佳乐, 边诣聪, 缪丽燕. 间变性淋巴瘤激酶抑制剂致肝损伤的危险因素研究[J]. 中国药物警戒, 2026, 23(2): 162-166.